EonBio is developing a cell-free technology platform to drive advancements in pharma R&D.

The challenge

$120.8 billion

projected global drug discovery market size by 2030


annual growth rate by 2030

Although the global drug discovery market is expected to continue growing, finding and developing new and effective drugs is still costly and time consuming.

EonBio’s innovative solution

EonBio’s cell-free technology recreates some of the specific pieces of cellular machinery on silicon chips without the unwanted interferences usually found in real, living cells. This way, the complex synthesis of proteins, metabolites, and other useful biomaterials can be streamlined and scaled, including novel and more effective drugs, and new-to-nature polymers. 

Competitive advantages

Capacity to produce novel and more effective drugs, in a faster and more economical way. It has the potential to drastically accelerate the pace of therapeutic innovation.

Cell-free technology may revolutionize other fields, namely manufacturing and the engineered synthetic materials field.


EonBio has been co-founded by eureKARE, Yeda, the commercial arm of the Weizmann Institute of Science, and built on the innovative research of Professor Roy Bar-Ziv’s lab.

Prof. Roy Bar-Ziv

Prof. Roy Bar-Ziv


Roy Bar-Ziv is an associate professor in the Department of Materials and Interfaces at the Weizmann Institute of Science, in Israel. His research combines physics, biology, and materials science to construct and explore cell-mimicking, artificial biological compartments on a chip. Roy Bar-Ziv was awarded the Krill Prize for Excellence in Scientific Research and is the winner of the eureKAWARDS 2021.

Luxembourg | France | Belgium

Subscribe to our news to keep in touch

Luxembourg | France | Belgium